We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pfizer has quietly launched what it’s calling the Pfizer Pledge, a pilot program that attaches an insurance-backed warranty to the performance of the company’s 10-year-old lung cancer drug Xalkori, promising money back. Read More
Bayer is investing in GRO Biosciences, a Boston-based company that is developing protein therapeutics for patients with autoimmune and metabolic diseases. Read More
Novartis has teamed up with Cambridge, UK-based Dunad Therapeutics to develop protein degradation therapies in a deal potentially worth more than $1.3 billion. Read More
Metagenomi will receive an undisclosed upfront payment, along with an equity investment, research funding and milestones-based payments for unspecified disease targets. Read More
Merck has inked a deal worth more than $525 million with preclinical biotech Synthekine to develop and commercialize novel cytokine therapeutics that focus on autoimmune diseases. Read More
Johnson & Johnson (J&J) has settled “substantially all” of the thousands of Risperdal (risperidone)-related lawsuits filed in the U.S. — which had alleged that the company’s anti-psychotic drug caused males to grow breast tissue. Read More
In 2018, Aegerion entered into a $40 million settlement with the Justice Department over charges that it marketed Juxtapid for uses the FDA never approved. Read More
Takeda Pharmaceuticals is expanding its off-the-shelf CAR-T cell program yet again, with the acquisition of GammaDelta Therapeutics, a company researching the unique abilities of gamma delta T-lymphocytes to attack blood cancers and solid tumors. Read More